Picankibart
Phase 3Small molecule
Picankibart is one of 68 small molecule programs targeting Psoriasis. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
67
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
605 competitors in Psoriasis
#DrugCompanyPhaseTrials
1Cosentyx
NovartisPreclinical
Stelara
Johnson & JohnsonPreclinical
Taltz
Eli LillyPreclinical
Bimzelx
UCBPreclinical
Humira
CCelltrion
Preclinical
Picankibart
IInnovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Phase 3
Raptiva
RochePreclinical
Remicade
OOrganon and Co
Preclinical
Siliq
BBausch Health Americas, Inc.
Preclinical
Victoza
Novo NordiskPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Psoriatic Arthritis1 trial
A Study of Picankibart in Patients With Active Psoriatic Arthritis
Recruiting·IInnovent Biopharmaceutical Technology (Hangzhou) Co., LTD.·Phase 2/3·NCT07295509·222 enrolled
Psoriasis1 trial
A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody Therapy
Active, not recruiting·IInnovent Biopharmaceutical Technology (Hangzhou) Co., LTD.·Phase 3·NCT06945107·308 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Picankibart. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details